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Abstract 
 
mTOR is a kinase protein meaning it phosphorylates target proteins affecting their 
cell signaling properties
1
. The drug Rapamycin, analogs of Rapamycin, and cell 
signaling proteins that interact with mTOR control the activities mediated by 
mTOR
1
. mTOR is located in the cytoplasm at a convergent point of many 
signaling pathways that regulate a multiplicity of cellular processes including 
metabolism that precede cell enlargement (cell “growth”), cell proliferation (cell 
division), and angiogenesis
1,2
. Cells with mTOR inappropriately activated can 
proceed with cell enlargement and cell proliferation in the absence of normal cell 
signaling
2
. Rapamycin and Rapamycin analogs can inhibit mTOR and prevent 
cell enlargement that precedes cell proliferation
3,4
.
 
 
 
We wanted to know if there is a concentration of Rapamycin that will inhibit cell 
enlargement and proliferation of normal human hematopoietic stem cells (HSC) 
under conditions that will still permit enlargement and proliferation of human 
U937 leukemia cells. We performed experiments where we treated HSC and 
U937 cells with Rapamycin. We compared the results of these experiments to see 
whether there is a dose response difference to Rapamycin between the two cell 
types.  
 
We found that cell size of both HSC and U937 leukemia cells was affected to 
comparable levels by Rapamycin at low nanomolar concentrations. However, 
Rapamycin appeared to have a startling differential effect on cell proliferation of 
HSC as compared to U937 cells. HSC proliferated very slowly or not at all in the 
presence of low nM concentrations of Rapamycin. U937 cells on the other hand 
were able to proliferate more strongly even at very high concentrations of 
Rapamycin. Rapamycin inhibited the rate of cell proliferation to some extent but 
it did not prevent the U937 cells from completing cell division and increasing in 
number.  
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  1 
Introduction 
 
The mammalian target of Rapamycin (mTOR) is a kinase protein that 
regulates many essential processes
1
. Cells with mTOR inappropriately “turned 
on” proceed with cell division often when they are not supposed to
2
. As Figure 1 
and Table 1 show, mTOR has been linked with many cancers, including breast 
cancer, colon cancer, prostate cancer, lymphoma, and melanoma
2
. 
 
 
Figure 1. Cancers in which mTOR is abnormally activated. 
 
 
© Novartis Pharmaceuticals Corporation  
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Table 1. The table lists mutations in upstream proteins that may lead to inappropriate activation of 
mTOR. Representative cancer types are listed. 
 
 
© Novartis Pharmaceuticals Corporation  
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mTOR is a protein kinase located in the cytosol at a converging point of 
numerous signaling pathways
1,2
. mTOR integrates the various signals and 
determines the appropriate cell response
1,2
. 
Since mTOR is a converging point of many signaling pathways, inhibiting 
mTOR may affect crucial cell processes such as cell proliferation, angiogenesis, 
or cell metabolism
2
. Abnormal expression of mTOR can lead to abnormal 
regulation of these crucial processes
2
. Inhibition of abnormal mTOR expression 
may provide an approach to cancer therapy. Inhibition of mTOR may enhance the 
effect of other therapeutic agents or methods, and indeed, Rapamycin and analogs 
of Rapamycin have been examined for anti-neoplastic efficacy
3,4
. In our 
laboratory on the other hand, we are proposing to exploit the over-expression of 
mTOR in leukemia cells as a novel approach to leukemia therapy rather than to 
inhibit mTOR activity.  
mTOR controls cell proliferation (cell division) by regulating the 
production of cyclin D1
2
. Cyclin D1 is involved in the regulation of cell passage 
through the G1-S cell-cycle checkpoint
2
. This regulation is performed via the 
activation of cyclin-dependent kinases 4 and 6 by cyclin D1
2
. Many cancers show 
overexpression of cyclin D1
2
. 
Angiogenesis, an essential process that provides nascent tumor cells with a 
blood supply, requires the production of many factors such as vascular endothelial 
growth factor (VEGF)
2
. mTOR controls the production of HIF1-α, also known as 
hypoxia-inducible factor
2
. It is the HIF1-α which activates the angiogenesis 
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factors
2,5
. In many cancers, HIF1-α is present at abnormal levels
2
. This can be due 
to overproduction or failure to degrade HIF1-α factors
2
.  
 mTOR also regulates cell metabolism
1,2,5
. When nutrient levels are high, 
mTOR activates protein synthesis
1,2,5
. Likewise, when nutrient levels are low, 
mTOR inactivation leads to down regulation of protein synthesis and cell growth 
arrest
1,2,5
. Many cancers grow inappropriately due to having mTOR “switched on” 
upregulating protein synthesis
2
. 
Our laboratory is particularly interested in exploiting inherent or 
chemotherapeutically-induced differences in cell size between normal cells and 
cancer cells as a possible approach to the physical destruction of enlarged cells. 
Rapamycin and analogs of Rapamycin can control cell size by inhibiting cell 
growth by specifically inhibiting mTOR
2,5
. Thus Rapamycin and Rapamycin 
analogs are antagonistic to cytoskeletal-directed anticancer chemotherapeutic 
agents such as Vincristine, Taxol, and Cytochalasin B that can cause cancer cells 
to become greatly enlarged. Cancer cells with abnormal expression of mTOR 
could become significantly enlarged under conditions where normal cells remain 
small because their mTOR expression is correct. Thus, a combination of 
cytoskeletal abnormalities along with errors in mTOR signaling may amplify the 
size differences between normal and cancer cells.  
We wanted to see if there is a dose-response effect of Rapamycin on cell 
size and proliferation of human stem cells (HSC) in culture and U937 leukemia 
cells in culture. We would like to know the conditions under which Rapamycin 
inhibits cell enlargement and proliferation of HSC more strongly than it does of 
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U937 leukemia cells. Moreover, we would like to know whether any 
concentration dependent effects are present. 
We performed experiments where we treated HSC and U937 cells with 
Rapamycin. We found that HSC and U937 cells are affected in terms of cell 
enlargement, although there may be a slight dose response difference between the 
two cell types. However, Rapamycin appears to have a startling effect on cell 
proliferation. As expected, HSC fail to proliferate in the presence of Rapamycin. 
U937 cells, on the other hand, proliferate strongly in the presence of Rapamycin. 
This differential characteristic may be further examined for sensitivity to physical 
destruction and/or interaction with cytoskeletal-directed chemotherapeutic agents.  
 
Literature overview 
The focus of this literature overview is on the mTOR protein kinase and 
its effects on cell size and the metabolic cycle. I will not elaborate on 
angiogenesis or cell proliferation more than I have already. For definitions of the 
various molecules mentioned please refer to Appendix A.   
Discovery 
 In the 1970s, the bacterial strain Streptomyces hygroscopicus was shown 
to produce a strong antifungal metabolite
5
. S. hygroscopicus is native to Easter 
Island
5
. This macrocyclic lactone metabolite was named Rapamycin after the 
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place of its discovery
1,5
. In the local language Easter Island is known as Rapa 
Nui
5
.  
Figure 2. Structure of Rapamycin showing the FKBP12-binding region and the mTOR-binding 
region. 
 
 
 
Rapamycin (Figure 2) suppresses immune response and cell proliferation
6
. 
Through gene knockout mutations the target of Rapamycin (mTOR) was 
identified in yeast
5
. Mutations mTOR1-1 and mTOR2-1 allowed the yeast 
Saccharomyces cerevisiae to be resistant to Rapamycin
5
. It was also shown that 
peptidyl-prolyl cis/trans isomerase FKBP12 is an essential intracellular co-factor 
for Rapamycin effectiveness
5,6
. Rapamycin forms a complex with FKBP12 that 
together binds and inhibits mTOR
5
.  
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Structure 
mTOR is highly conserved across eukaryotic species
5
. Every eukaryote 
genome examined so far: yeast, algae, plants, flies and mammals among many, all 
contain the mTOR gene
5
. Yeast have been found to contain 2 mTOR genes
5
. 
Higher organisms contain only 1 gene
5
. 
mTOR is a large protein (about 280 kDa)
5,6
. About 40%–60% of the 
mTOR primary sequence is identical to the phosphatidylinositol kinase-related 
kinase (PIKK) family of proteins
5
. At the carboxy-terminus end of mTOR the 
PIKK family have a serine/threonine protein kinase domain
5,6
. This domain shares 
features of the catalytic domain of phosphatidylinositol 3-kinases (PI3Ks) and 
PI4Ks
5,6
. 
The amino-terminus of mTOR contains the FKBP12-Rapamycin binding 
domain (FRB) which is the binding site of Rapamycin (Figure 3)
5
. Mutations in 
this domain yield mTOR proteins that no longer respond to inhibition by 
FKBP12-Rapamycin complex
5
. Other selective mutations have uncovered many 
domains of protein-protein interaction such as the C-terminal FAT and FATC 
domains that are found in all PIKKs
5
. Another indication of protein-protein 
interaction is the presence of HEAT sequences found at the amino terminus of 
mTOR
5
. These HEAT sequences may extend and form helices offering regions 
for protein-protein interaction
5
. 
mTOR forms two distinct complexes (Figure 4)
5,7
. mTOR complex 1 
(mTORC1) is sensitive to Rapamycin
1,5
. This complex dictates how the cell 
grows
1,5
. mTOR complex 2 (mTORC2) is Rapamycin insensitive
1,5
. It dictates the 
  8 
actin cytoskeleton organization
1,5
. As such it controls cell motility, morphology, 
position, polarization and location. mTORC2 is poorly understood
5
. The 
complexes are distinct in the associated proteins they bind
5,7
. Both are multimers, 
likely dimers
5,7
. 
 
Figure 3. The binding of FKBP12-Rapamycin complex to the FRB domain of mTOR. 
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Figure 4. The structure of the two distinct mTOR complexes and their respective functions.  
Wullschleger, S., Loewith, R., Hall, M.N. (2006). TOR Signaling in Growth and Metabolism. Cell 
124. 471-484.  
 
Early Development  
 Experiments which involve the deletions of the mTOR gene in 
Caenorhabditis elegans or in Drosophila melanogaster result in embryos that 
show developmental arrests similar to starved larvae
5
. This indicates that mTOR 
is important in the early stages of development where cell growth and 
proliferation are of utmost importance
5
. For example, Bateman and McNeill have 
shown that overexpression of mTOR in Drosophila accelerates differentiation
5
. 
Likewise, underexpression of mTOR in Drosophila leads to slower 
differentiation
5
. 
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 Experiments performed on mice also indicate the essentiality of mTOR 
function
5
. Mouse embryos with missing mTOR show developmental problems 
and often fail to survive because the defective embryos suffer from amino acid 
deprivation
5
. When mouse cells are treated with Rapamycin, they also fail to 
proliferate
5
.  
Cell growth 
In order to maintain homeostasis cells need to respond to nutrients 
appropriately. When nutrients are abundant cells usually respond by increasing 
their metabolic rate
5
. When mTOR is activated, cells show very high rates of 
nutrient transport, ribosome biogenesis, and protein synthesis
1,5
. 
Conversely, when nutrients are lacking cells will downregulate metabolic 
rates to better conserve energy
5
. Studies of Rapamycin treated yeast have shown 
that when mTOR is inhibited, translation is downregulated; macroautophagy and 
other stress-response systems are initiated
1,5
. 
Moreover, studies in yeast have also shown that mTOR is not only 
responsible for how much the cell grows, but also where it grows
1,5
. mTOR2, not 
mTOR1, regulates the polarization of actin skeleton
1,5,7
. In yeast that reproduce by 
budding, mTOR2 allows actin to polarize toward the bud causing protein 
synthesis and sequestration to be localized in the bud
5
. This function of mTOR2 is 
insensitive to the effects of Rapamycin
5
. The effect of mTOR2 on actin 
organization is conserved across organisms
5
. 
 
  11 
Cell Growth Regulation Upstream 
Growth Factors 
 mTOR is important in regulation of cell growth because it integrates the 
various signals that the cell experiences such as the presence or absence of growth 
factors (GF), nutrients, energy or stress
1,5
. When growth factors are present, 
mTOR will respond via the PI3K pathway
5
. For example, Figure 5 shows how 
insulin (a GF) stimulates the pathway. Upon its binding to the receptor, the insulin 
receptor substrate (IRS) is phosphorylated which in turn attracts PI3K
5
. PI3K-IRS 
complex then converts phosphatidylinositol-4,5-phosphate (PIP2) into 
phosphatidylinositol-3,4,5-phosphate (PIP3)
5
. Phosphatase and tensin homolog 
(PTEN), the enzyme that acts as a tumor suppressor, may antagonize the 
accumulation of PIP3
5
. 
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Figure 5. Upstream and downstream mTOR signaling pathways. 
 
Wullschleger, S., Loewith, R., Hall, M.N. (2006). TOR Signaling in Growth and Metabolism. Cell 
124. 471-484.  
 
  
Subsequently, PIP3 will recruit PDK1 and Akt to the membrane and 
activate them by phosphorylation
5
. mTOR recognizes the PI3K pathway through 
the tuberous sclerosis proteins TSC1 and TSC2
5
. TSC1 is a hamartin and TSC2 is 
tuberin
5
. Both act as a heterodimers that antagonize mTOR
5
. When insulin is 
present, activated Akt phosphorylates TSC2, thereby rendering it inactive and 
unable to form the heterodimer
1,5
. 
 TSC2 is a GAP (GTP-ase activating protein) for the Rheb molecule, which 
is a GTPase
5
. There is no consensus on whether Rheb directly binds to the mTOR 
kinase domain; however, there is agreement that Rheb induces a conformational 
change in mTORC1, leading to the activation of mTORC1
5
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Nutrients 
  mTOR1 is regulated by amino acids, particularly the amino acid leucine5. 
When leucine is absent mTOR effectors S6K1 and 4E-BP1 are 
dephosphorylated
5
. When leucine is re-added the dephosphorylation is reversed
5
. 
 One way this regulation might come about is through the interaction of 
amino acids with the TSC1-TSC2 complex
5
.The presence of amino acids has been 
suggested to either inhibit the TSC1-TSC2 complex or to stimulate the Rheb 
molecule
5
. When TSC-1 is inactivated the cell does not respond properly to the 
presence of amino acids
5
. Other studies suggest that amino acids affect the 
interaction and binding of Rheb and mTOR
5
. More recent studies have implicated 
another molecule, hVPS34, a class III PI3K that signals to mTOR independently 
of the TSC-Rheb complex
5
. The mechanism is not clear
5
. 
 
Energy 
 The cell gauges the levels of energy based on the levels of AMP-activated 
protein kinase (AMPK)
1
. Cell growth requires a lot of energy to synthesize 
proteins at a high rate. Low levels of energy are characterized by a high 
AMP/ATP ratio that activates AMPK
1,5
. When activated, AMPK inhibits protein 
synthesis and activates ATP synthesis
1,5
. AMPK directly phosphorylates TSC2, 
enhancing its activity
5
. Experiments done using the AMPK analog called AICAR 
have shown mTORC-1 inhibition of S6K1 and 4E-BP1
5
. 
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Stress 
 Cells respond to stress, such as hypoxia (low oxygen) by downregulating 
processes that require a lot of energy, such as cell growth
5
. When a cell 
experiences hypoxia it downregulates mTOR and protein synthesis is inhibited
1
. 
Experiments performed on Drosophila and mammalian cells have shown that 
cells recognize hypoxia through the REDD1 and REDD2 proteins
5
. When the cell 
experience hypoxia, HIF1 stimulates the production of REDD molecules
5
. REDD 
molecules act downstream of Akt but upstream of TSC
5
. REDD inhibits mTOR1
5
. 
Since hypoxia leads to eventual ATP depletion, it is suggested that the AMPK 
pathway and REDD pathway are interrelated
5
. The mechanism is still unknown
5
. 
 Cells experience other stresses
5
. When p53 senses DNA damage it signals 
to mTOR via the AMPK-TSC2 signaling pathway
5
. Other stresses include the 
presence of reducing agents in the environment
5
. Reducing agents have been 
suggested to inhibit mTOR via a redox sensor in the FAT domain of mTOR
5
. 
 
Cell Growth Regulation Downstream 
 
Ribosome Biogenesis 
 The creation of ribosomes is a very energy-consuming process
5
. It is 
essential for a cell to have a ribosome control mechanism that responds to the 
changes of cellular energy levels
5
. Studies have shown that mTOR controls the 
synthesis of ribosomes by controlling the transcription of RNA polymerase I-
dependent rRNA genes, RNA Polymerase II dependent ribosomal protein genes, 
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RNA Polymerase III dependent tRNA genes and also by controlling 35S rRNA
5
. 
In humans and mice, mTOR controls ribosome synthesis by inhibiting these 
genes
5
. mTOR has been shown to control transcription by forming complexes 
with transcription initiation proteins, such as Pol I associated TIF1A
5
. Cells 
treated with Rapamycin showed inactivation of TIF1A and prevention of 
transcription
5
. FHL1 Pol II associated transcription factor has been shown to be 
essential for regulation of Pol II-dependent RP gene expression
5
. 
 
Transcription/Translation 
 Translation is regulated by S6K1 and 4E-BP, both of which are regulated 
by mTOR
5
. mTOR activates S6K1 through phosphorylation at Thr389
5
. The 
second phosphorylation comes from PDK1
5
. It is unknown how S6K1 augments 
translation
5
. mTOR 1 phosphorylation has been shown to be important in the 
nuclear localization of several transcription factors
5
.  
 
Actin 
 mTOR2 complex controls the polarization of actin molecules
1,5
. mTOR 
signals to actin through Rho1 GTPase
5
. Rho1 then signals to PKC1 which in turn 
activates the MAP kinase pathway that reorganizes the actin cytoskeleton
5
. How 
TOR signals to Rho1 is not understood
5
 
 Rosner et al. show that the effects on cell cycle and cell size by mTORC1 
and mTORC2 appear to be separate
7
. However, mTORC2 appears to not only 
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control actin reorganization but also regulates cell size and cell cycle via Akt, 
TSC2 and Rheb cell signaling
7
. This is independent of mTORC1 signaling
7
. 
 
Macroautophagy 
 Macroautophagy occurs when cells that are without nutrition for a 
prolonged time begin to degrade cytoplasmic contents to maintain energy levels
1
. 
ATG1 is a kinase that activates macroautophagy
5
. mTOR has been implicated in 
yeast and higher organisms in controlling this process
5
. Yeast studies have shown 
that TOR inactivates a protein kinase ATG1
5
. When mTOR is inactivated, 
macrophagy is initiated and the cells begin this catabolic process
5
.  
 
Metabolism  
 Metabolic processes such as amino acid synthesis, glucose homeostasis 
and fat metabolism are controlled by mTOR as well
5
. Rapamycin treatment 
inhibits adipogenesis, which is poorly understood
5
. However, the mechanism 
seems to involve mTOR and S6K1 since mTOR signals to S6K1
5
. S6K1 mutants 
inhibit fat accumulation
5
. Moreover, flies with inactivated mTOR show fat 
deficiency
5
. 
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Materials 
 
Fetal Bovine Serum, Atlanta Biologicals, premium, triple 0.1 µm filtered. 
 
StemSpan SFEM: Serum Medium for Expansion and Culture of Hematopoietic 
Cells, Stem Cell Technologies. 
 
Amphotericin B (Fungisone) 0.250 µg/ml, Sigma. 
 
Penicillin-Streptomycin: 10,000 units penicillin and 10 mg streptomycin per ml in 
0.9% NaCl, Sigma. 
 
L-Glutamine: 200 mM, Sigma. 
 
Gentamycin Sulfate: 10 mg/ml, BioWhittaker. 
 
StemSpan Cytokine Cocktails, 100X (Flt-3, SCF, IL-3, IL-6) Stem Cell 
Technologies. 
 
Iscove’s Modified Dulbecco Medium with NaHCO3 and 25 nM Hepes. No 
glutamine, thioglycerol, BME, BioWhittaker. 
 
Rapamycin: Sigma. 
 
Methods 
Experiment 1 
The U937 Cells: The R1A Line Day 8 plateau-phase cells were checked for 
viability. They were sub-cultured to 5 x 10E4 Cells/ml in Iscove’s Modified 
Dulbecco’s Medium with 20% FBS, 1% FGZ (Amphotericin B) (2.5 µg/ml), 1% 
Gln (2 mM), 2% Pen-Strep (200 units penicillin, 200 µg streptomycin per ml), 
0.5% Gentamycin (200 µg/ml) in 5% CO2 at 37
o
C. They were grown for 24 
hours. Cells were counted before seeding and checked for viability. The cells 
were seeded 500 µl into 1 ml wells in a 48-well plate. Rapamycin 40 µM in EtOH 
was given to final concentrations of 800, 400, 200 (10 µl, 5µl, 2.5 µl). A 5 µM 
Rapamycin Stock Solution in EtOH (10 µl, 5 µl, 2.5 µl) was used to give 100, 50, 
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and 25 nM Rapamycin.  Control wells were either untreated or treated with 1.9% 
EtOH. Cells were Coulter counted at days 1 and 4, at every micron size from 8µm 
to 22µm. 
 
Human Stem Cells: Were revived on March 11, 2009, from cells that were stored 
at the temperature of -86
o
C on November 17, 2006. They were grown for one 
week in 20% FBS Iscove’s, 1% FGZ, 1% Gln, 1% Stem Span from Stem Cell 
Technologies. Before seeding cells were counted with a hemocytometer and 
checked for viability using trypan blue. The cells were seeded in a volume of 500 
µl into 1 ml wells of 48-well plate. Rapamycin treatment was same as for U937 
cells. The cells were Coulter counted at days 1, 4, 8, and 9. They were counted at 
every micron size from 8µm to 18µm. 
 
Experiment 2 
U937 Cells: The R1A Line Day 6 late log-phase cells were checked for viability. 
They were sub-cultured to 5 x 10E4 Cells/ml in 20% FBS Iscove’s, 1% FGZ, 1% 
Gln. They were grown for 24 hours. Rapamycin solutions were prepared by 
making 4 µM Rapamycin in 95% EtOH using 40 µM Rapamycin Solution. At the 
day of treatment there were 1.3 X 10E5 Cells/ml in 4 ml flasks. There were 8 
flasks total. Six flasks (40, 20, 10, 5, 2, 1 nM) were treated with 40, 20, 10, 5, 2, 
and 1µl of 4 µM Rapamycin, respectively. Control cells were either untreated or 
treated with 0.95% EtOH. Cells were Coulter counted at days 1 and 4, at every 
micron size from 8µm to 22µm. 
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Three days later Rapamycin was removed from flask. Rapamycin-free medium 
was added (medium dilution is 1:100 after addition of 5 ml medium to 50 µl 
residual medium and cells). Growth was monitored at 3, 6, 9, and 21 hours after 
Rapamycin-removal. 
 
Experiment  3  
U937 Cells: R1A Line Day 4.5 log-phase cells were checked for viability. They 
were diluted 1:4 to ~5.5 x 10E4 Cells/ml in 20% FBS Iscove’s, 1% Gln, 1% FGZ. 
One ml of cells was inserted into the 1st well in 8 well series of 48 well plate. 
Subsequent 7 wells received 0.5 ml of cells. Well 1 received 8 µl of 4 µM 
Rapamycin in 95% EtOH. Serial transfer of 500 µl from 1st well through 7th well 
gave 32, 16, 8, 4, 2, 1, 0.5 nM Rapamycin concentrations. The last well received 
no transfer (untreated/control U937 cells). Second to last well (0.5 nM) had 1.0 ml 
cells and not 500 µl. Cells were counted with Coulter Counter after 72 hours.  
 
Stem Cells:  Cells were freshly prepared by Dr. Prabal Banergee, Upstate Medical 
School, June 26, 2009. They were grown in Stem Cell Expansion Medium + 1% 
FGZ + 1% Gln + 5% FBS for four days and checked for viability. Cells were 
diluted 1:10 with Stem Cell Expansion Medium + 5% FBS + 1% Gln, 1% FGZ to 
~ 5 x 10E4 Viable Cells/ml. Three days later they were Rapamycin-treated in 7 
wells as for U937 cells. Rapamycin treatment was the same as for U937 cells. 
U937 and Stem Cells were counted with a Coulter Counter after 72 hours.  
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Results/Discussion 
Experiment 1 
 
We wanted to determine the dose-response effect of Rapamycin on HSC and 
U937 human leukemia cells over the Rapamycin range from 800 nM to 25 nM. 
Table 2 lists the effect of Rapamycin treatment on cell size (average cell volume) 
of HSC and U937 leukemia cells. 
 
Table 2. The effect of 800 to 25 nM Rapamycin concentrations on cell size inhibition of U937 
leukemia cells and HSC.  
 
 Rapamycin 
U937 Avg. 
Volume   
HSC Avg 
Volume   
Conc (nM) 8u & < 
% 
inhibition  8u & < 
% 
inhibition 
0 2083   900   
800 (1.9% EtOH) 1462 30 872 3.1 
400 (0.98% EtoH) 1458 30 715 21 
200 (0.48% EtOH) N/A N/A 645 28 
100 (1.9% EtOH) 1500 28 682 24 
50 (0.98% EtoH) 1536 24 619 31 
25 (0.48% EtOH) 1829 12 698 24 
 
Figure 6a shows the effect of 800 nM and 400 nM Rapamycin on the size 
distribution of early log U937 cells 2 days after Rapamycin treatment. 200 nM 
results are not included due to an experimental error.  
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Figure 6a. The effect of Rapamycin on average cell volume of U937 cells two days after 
treatment. Red bars represent average volume of cells 13µm and higher. Blue bars represent the 
average volume of cells 8µm and higher. 
 
Average cell volume of the U937 cells decreased. When compared with control 
cells, 800 and 400 nM Rapamycin concentrations decreased average cell volume 
by 30%. The 100 nM concentration inhibited cell size by 28%. The 50 nM 
Rapamycin inhibited cell size by 24%. The 25 nM Rapamycin concentration 
inhibited cell size by 12%. EtOH treated cells showed slight size inhibition, about 
6.5%.   
 
Table 2 and Figure 6a both show the predicted response of human leukemia cells 
to Rapamycin in terms of cell size. All bar graphs in Figure 6a show cell size 
inhibition. At this point, it appeared that lower Rapamycin concentrations affected 
cell size less than did the higher Rapamycin concentrations.   
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We also checked the effect of Rapamycin on cell proliferation.  
Figure 6b. Linear growth graph representing the effect of Rapamycin on cell proliferation of U937 
leukemia cells. 
 
As figure 6b shows, Rapamycin appears to have an effect on cell proliferation. 
The data at this point show no concentration-dependent effect of Rapamycin on 
cell proliferation since 800 nM and 100 nM cells were inhibited the most. This 
may be due to the different concentrations of EtOH that were used to dissolve 
Rapamycin. Proliferation was inhibited by about 50% to 75% but the cells still 
continued to proliferate. U937 cells can “grow through” the Rapamycin cell 
enlargement block. 
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Figure 6c. Exponential curve graph showing the effect of Rapamycin on cell proliferation of U937 
leukemia cells. 
 
Figure 6c shows an exponential growth curve of the effect of Rapamycin on cell 
proliferation of the U937 cells. Again, there is no evidence of a dose dependent 
effect of Rapamycin on cell proliferation of U937 leukemia cells. 
 
Next we wanted to see whether human stem cells show a similar trend, and we 
wanted to establish the dose response of HSC to Rapamycin.  
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Figure 6d. The effect of Rapamycin on the average volume of HSC two days after Rapamycin 
Treatment. The blue bars represent the average volume of cells 8µm or higher.  
 
Figure 6d shows that HSC treated with Rapamycin become smaller. EtOH control 
cells had reduced cell volume by 8.5% as compared with non-EtOH control cells. 
As table 2 lists, the 800 nM concentration inhibited cell size by 3.1%, 400 nM 
concentration inhibited cell size by 21%, and 200 nM concentration inhibited cell 
size by 28%. Rapamycin at 200 nM actually reduced cell volume more than the 
400 nM or 800 nM dose. It appears that 800 nM did not affect cell volume at all.  
 
The 100 nM Rapamycin concentration inhibited cell size by 24%. The 50 nM 
concentration inhibited cell size by 31%. The 25 nM concentration inhibited cell 
size by 22%. Rapamycin at 50 nM reduced HSC cell volume more than any of the 
other Rapamycin concentrations did. There was no evidence of a dose dependent 
response of HSC to Rapamycin concentrations.  
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Figure 6e shows the effects of Rapamycin on cell proliferation. 
Figure 6e. Effect of 800 nM to 25 nM Rapamycin on cell proliferation of HSC.  
 
At day 2 of Rapamycin treatment, all Rapamycin concentrations permitted slight 
cell proliferation. However, cell proliferation was markedly reduced by day 8 of 
Rapamycin treatment. The cell number went down noticeably by day 8. This 
could be due to cell death or cell differentiation. Rapamycin removal experiment 
should be performed to establish toxicity of Rapamycin for both HSC and U937 
cells.  
 
From this experiment we concluded that 1.9% EtOH itself affects cell 
proliferation and cell volume slightly for both U937 human leukemia cells and for 
human stem cells. This may be important since we used EtOH as a Rapamycin 
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solvent. Moreover, we used different concentrations of EtOH. Future experiment 
should use Rapamycin dissolved in one constant concentration and the results 
should be compared to these results.  
 
Stem cells are generally much smaller in diameters and average cell volumes than 
are U937 leukemia cells. Our experiment shows that this characteristic is 
maintained despite Rapamycin treatment. Both types of cells had inhibited cell 
size and lower cell volume when treated with Rapamycin. No apparent 
differential dose-response to Rapamycin between the HSC and U937 cells was 
observed. Rapamycin treated stem cells showed much lower cell proliferation, as 
expected. U937 cells on the other hand continued to proliferate in the presence of 
Rapamycin.  
 
Stem cells showed an unusual response to very high doses of Rapamycin at 800 
nM by failing to be inhibited in their loss of cell volume and by continuing to 
proliferate slightly. Moreover, stem cells used here are only 52% trypan blue 
viable, growing 8 days after freezer revival. Rapamycin effects should be 
determined on freshly-derived stem cells never frozen, and in full viable 
proliferation. 
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Experiment 2  
In this experiment we expanded on the previous experiment by lowering the 
Rapamycin concentration used. We wanted to see the effect of a 3-day treatment 
with Rapamycin on U937 leukemia cells over a concentration range from 40 nM 
to 1nM. We looked at cell size, cell proliferation and trypan blue viability. Table 
3 shows the effect of Rapamycin on average cell volume of U937 cells. We also 
looked at the re-growth of leukemia cells after Rapamycin was removed.  
 
Table 3. The effect of Rapamycin on average cell volume of U937 cells 2 days after treatment.  
 
 Rapamycin U937 Avg. Volume   
Conc (nM) 8u & < % inhibition  
0 2048  
40 (0.95% EtOH) 1579 23 
20 (0.5% EtOH) 1682 18 
10 (0.25% EtOH) 1720 16 
5 (0.12% EtOH) 1877 8.3 
2 (0.05% EtOH) 1723 16 
1 (0.025% EtOH) 2017 1.5 
 
Figure 7a shows size-distribution of control cells, 0.95% EtOH treated cells and 
40 nM Rapamycin treated cells at day 2. 
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Figure 7a.  Size-distribution of control cells, 0.95% EtOH treated cells and 40 nM Rapamycin 
treated cells at day 2. 
 
The controls varied slightly at 2 days. The mid-log phase cells (at the beginning 
of Rapamycin treatment) got smaller in 2 days as they reached plateau-phase. 
EtOH treated cells when compared to control cells at day 0 had cell size inhibition 
of 15%. EtOH treated cells compared to day 2 control cells had 6.25% size 
inhibition. Subsequent cell size inhibition calculations use the Day 2 plateau-
phase cells as control cells. The 40 nM Rapamycin treated U937 cells had 23% 
cell size inhibition. 
 
Figure 7b shows the effect of 40 (repeated from above), 20 and 10 nM Rapamycin 
concentrations on U937 cells. 
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Figure 7b. The effect of Rapamycin 40, 20 and 10 nM concentrations on the cell size of U937 
cells. 
 
20 nM Rapamycin concentration showed 18% cell size inhibition. The 10 nM 
Rapamycin treatment showed 16% cell size inhibition.  
 
Figure 7c shows Rapamycin concentration range of 10, 5, 2, and 1 nM at day 2 of 
treatment. 
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Figure 7c. The effect of Rapamycin concentration range of 10, 5, 2, and 1 nM at day two of 
treatment on the average cell volume of U937 leukemia cells.  
  
5 nM Rapamycin inhibited cell size by 8.3%. The 2 nM inhibited cell size by 
16%, much more than the 5 nM dose. The 1 nM treatment inhibited cell size by 
1.5%. It appears that somewhere between 1 nM to 5 nM Rapamycin begins to 
allow for cell enlargement.  
 
The 2 nM concentration result is difficult to interpret because it might be due to 
experimental error. The 2 nM treatment should be repeated for both HSC and 
U937 cells to see whether Rapamycin affects cell size of HSC more strongly than 
of U937 cells.  The 1 nM Rapamycin did not seem to affect the U937 cells.  
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Figure 7d shows the effect of Rapamycin on cell proliferation of the U937 
leukemia cells. 
 
Figure 7d. The effect of 40 nM to 1 nM Rapamycin on cell proliferation of U937 cells two days 
after treatment. 
Cell proliferation was inhibited at 40 nM to 1nM Rapamycin concentrations. 
Higher Rapamycin concentrations (40 nM) inhibited cell proliferation more 
strongly than did lower Rapamycin concentrations (1 nM). However, Rapamycin 
continued to permit cell proliferation. Rapamycin appears to not prevent U937 
cells from proliferating.  
 
After 3 days of treatment with 20 nM Rapamycin, removal of 99% of the 
Rapamycin (50 µl remaining after centrifugation and removal of Rapamycin-
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medium, and suspension in 5 ml of medium) cells showed re-growth and increase 
in average volume between 9 and 21 hours after Rapamycin removal. Rapamycin 
appeared to have no toxicity on the treated cells. 
 
We concluded that 0.95% EtOH affects cell proliferation and cell volume 
significantly, and should be taken into consideration when performing other 
experiments.  
Rapamycin shrinks cell volume and inhibits proliferation at 40, 20, and 10 nM. It 
continues to have an effect at 5 nM and 2 nM concentrations. However, the effect 
of Rapamycin at concentrations 40 to 1 nM on cell size and proliferation is less 
strong than the effect of Rapamycin at concentrations 800 to 25 nM.  
U937 cells can increase in size and can proliferate in the presence of 1 nM 
Rapamycin. It is important to determine the does-response limit of human stem 
cells and compare it to the U937 cells. 
In addition, Rapamycin can be removed from cells treated with 20 nM Rapamycin 
and cells can begin to proliferate after 9 hours in Rapamycin-free medium 
(residual Rapamycin = 0.2 nM). 
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Experiment 3 
In this experiment we compared the Rapamycin dose-response of HSC and U937 
cells over the concentration range 32 nM to 0.5 nM. This time we used freshly 
derived human stem cells that we obtained from Dr. Prabal Banerjee, Upstate 
Medical School.  
Stem cells used for Rapamycin treatment were Day 7 growth cells, 65% trypan-
blue viable. They were grown in a multi-well plate with Rapamycin for 3 days 
from Day 7 to Day 10. In untreated control cells viability was 97% by day 10.  
Table 4. The effect of Rapamycin on average cell volume and cell size inhibition of HSC and 
U937 cells.  
  
U937 Avg. 
Volume   
HSC Avg 
Volume   
Conc 
(nM) 8u & < % inhibition  8u & < % inhibition 
0 1800   742   
32 1465 19 653 12 
16 1384 23 671 9.5 
8 1443 20 668 10 
4 1504 16 730 1.6 
2 1609 11 723 2.6 
1 1723 4.8 723 2.6 
0.5 1759 2.3 760 -0.24 
Table 4 shows the percent inhibition of Rapamycin on HSC and U937 cells on 
cell size. Both types of cells showed size inhibition; however, HSC cells were 
more strongly inhibited than were the U937 cells. The 0.5 nM concentration of 
Rapamycin had no effect on cell size.  
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Figure 8a shows the differential effect of Rapamycin on U937 cells and HSC in a 
graphical form. 
Figure 8a. The effect of Rapamycin on cell proliferation and average cell volume of U937 cells 
and HSC cells.  
 
Rapamycin reduced cell volume for both U937 leukemia and HSC by about 10 to 
20%. The differential dose response of U937 cells and HSC might exist in the 
range of 0 nM to 4 nM Rapamycin concentration. The data are inconclusive at 
this moment. 
Cell proliferation on the other hand showed a startling result. Both figures 8a and 
8b show cell growth and proliferation. As compared to a 10-fold increase of the 
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untreated cells, U937 cells were able to proliferate in the presence of 8 to 1 nM 
Rapamycin by 6- to 8 fold-. 
Figure 8b. The effect of Rapamycin on cell proliferation and average cell volume of U937 
leukemia cells and HSC 
 
On the other hand, when compared to the 3-fold increase of untreated cells, HSC 
did not proliferate at all at 8 nM, and proliferated weakly at 2nM and 4 nM 
Rapamycin.  
Leukemia cells were Rapamycin-treated in 20% FBS, whereas Stem Cells were 
treated in SCEM to allow for stem cell proliferation. If U937 leukemia cells 
proliferate in SCEM, Rapamycin treatment should be done in SCEM for both 
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Stem Cells and U937 cells to make sure that Rapamycin  is not being bound by 
20% FBS, reducing its effect on leukemia cells. 
Rapamycin treatment should be repeated at concentrations from 8 nM, serially 
diluted to 4, 2, 1, 0.5, 0 25, 0.125 nM.  Two sets of wells should be used for U937 
and two for Stem Cells.  Treatment should be in identical media allowing for 
growth of both stem cells and U937 cells. 
Conclusions 
In these laboratory experiments we wanted to establish whether there are 
conditions under which Rapamycin will affect HSC more strongly than U937 
leukemia cells. We found that, in terms of cell enlargement, there may be a 
differential dose-response to Rapamycin between human leukemia cells and 
human stem cells to Rapamycin; however, the data are inconclusive and further 
analysis is required. Ultimately, we would like to see if there is a concentration of 
Rapamycin that will inhibit cell enlargement of normal cells while still permitting 
enlargement of leukemia cells by amplifying the size differences between normal 
and leukemia cells without additional treatments.  
More startling is lack of effect of Rapamycin on cell proliferation of U937. As 
expected, HSC had inhibited cell proliferation. U937 cells, while inhibited 
slightly, continued to proliferate without increasing in size. This deserves further 
investigation.  
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Our laboratory is particularly interested in exploiting inherent or 
chemotherapeutically-induced differences in cell size between normal cells and 
cancer cells as a possible approach to the physical destruction of enlarged cells. 
Since Rapamycin and analogs of Rapamycin can control cell size by inhibiting 
cell growth, they are antagonistic to cytoskeletal-directed anticancer 
chemotherapeutic agents such as Vincristine, Taxol, and Cytochalasin B that can 
cause cancer cells to become greatly enlarged.  
 
Data already exists that suggests that Rapamycin can synergistically enhance or 
inhibit chemotherapy.
3,4
 We would like to see whether Rapamycin concentration 
will permit the leukemia cells to be trapped in an enlarged state by cytoskeletal-
directed agents that trap dividing cells in mitosis or at cytokinesis while normal 
cells remain out of the cell cycle and remain small. Moreover, cytoskeletal-
directed agents prevent cells from proliferating. Since Rapamycin inhibited cell 
proliferation slightly while inhibiting HSC proliferation completely, the drug-drug 
interaction of Rapamycin and cytoskeletal-directed agents might be a potential 
subject of interest. Further experiments should determine the interaction between 
Rapamycin and its antagonist agents in both human leukemia cells and human 
stem cells. 
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Appendix A  
Glossary 
 
VEGF  – vascular endothelial growth factor; plays a role in angiogenesis by 
attracting and organizing vascular endothelial cells
2,8,9
. 
 
HIF1-α  – hypoxia-inducible factor 1α; A transcription factor involved in 
angiogenesis, metabolism, proliferation, motility, adhesion, and survival
2,9,10
. 
 
FKBP12  –  FK506 binding protein; protein folding chaperone
8,9,10
. 
 
FRB  –  FKBP12-Rapamycin binding domain
5
. 
 
PIKK  – phosphatidylinositol kinase-related kinase family, protein family that 
phosphorylates other proteins to adjust their function
8,9
. 
 
PI3K – phosphatidylinositol 3-kinase; oncoprotein that phosphorylates lipids, 
resulting in their recruitment to the cell membrane.
2,5,8,9
  
 
PI4K – phosphatidylinositol 4-kinase
5
. 
 
FAT and FATC – a conserved kinase domain on the C-terminus of PIKK, 
mediates protein-protein interaction and association
11
. 
  
HEAT sequences – amino acid sequences (varying from 30 to 60 residues) that 
appear in various proteins, including kinases; the motif consists of particular 
arrangement of A and B helices; thought to play a role in protein/protein 
interactions
12
. 
 
PIP2 – phosphatidylinositol-4,5-phosphate
5
.  
 
PIP3 – phosphatidylinositol-3,4,5-phosphate
5
.  
 
PTEN – phosphatase and tensin homolog
2
. 
 
PDK1 – 3-phosphoinositide-dependent protein kinase 1
9
. 
 
Akt – enzymes that are members of the serine/threonine-specific protein kinase 
family; involved in metabolism, proliferation and growth regulation
2,9,10
. 
 
TSC1 – Tuberous sclerosis protein 1, hamartin protein, tumor suppressor
2
. 
 
TSC2 – Tuberous sclerosis protein 2, tuberin, believed to be a tumor suppressor, 
stimulates  
GTP-ases
2
. 
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Rheb – Ras homolog enriched in brain, belongs to the Ras superfamily of GTP-
ases, functions in cell proliferation
2
. 
 
S6K1 – S6 kinase 1, phosphorylates ribosomal 6S protein
9
. 
 
4E-BP1 – eukaryotic initiation factor 4E binding protein 1, initiate translation
9
. 
 
hVPS34 – a class III PI3K required for activation of p70 S6 kinase
5
. 
 
AICAR – 5-Aminoimidazole-4-carboxamide-1- -4-ribofuranoside (AICAR),
 
an 
analog of AMP, is widely used as an activator of AMP-kinase
 
(AMPK), a protein 
that regulates the responses of the cell to
 
energy change
13
. 
 
REDD1 and REDD2 – hypoxia-inducible genes, suppress mTORC1
5,14
. 
 
Pol – polymerase
5
. 
 
TIF1A – tripartite motif-containing 24, also known as transcriptional intermediary 
factor 1 alpha, involved in regulation of transcription
8,10
.  
 
FHL1–   four and a half LIM domains (Pol II associated transcription factor), 
involved in many cellular processes
8
. 
 
Rho1 –   GTP-binding protein of the Rho subfamily of Ras-like proteins, involved 
in establishment of cell polarity 
 
PKC1 – protein kinase C1, pertains to a family of serine/threonine protein kinases 
grouped by their activation mechanism
8
. 
 
MAP(K) – mitogen-activated protein kinase; are serine-threonine kinases that 
regulate a wide variety of cellular functions
8
. 
  
ATG1 – Autophagy-specific gene 1; involved in autophagy
8
. 
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Capstone Summary 
mTOR in Cell Signaling and Cell Size Enlargement as a Target for the Chemico-
Physical Therapy of Cancer 
In 1970, Streptomyces hygroscopicus bacteria were discovered in the soil 
samples from Easter Island.
5
 S. hygroscopicus was found to produce a strong 
antifungal compound.
1
 This compound was named Rapamycin after the place of 
its discovery.
5
 In the local language, Easter Island is called Rapa Nui.
5
  
At a later date the cellular protein target of Rapamycin was identified in 
mammalian cells.
5
 The protein was named “mTOR” for mammalian target of 
Rapamycin.
1,5
 mTOR is a kinase protein, meaning it adds a phosphate group to 
other proteins in order to adjust their function.
5
 About 40%–60% of mTOR’s 
primary amino acid sequence is identical to a larger family of kinases, the 
phosphatidylinositol kinase-related kinase (PIKK) family.
5
  
mTOR is a large protein; it is about 280 kDa.
5
 It is located in the 
cytoplasm at a convergent point of many signaling pathways, which allows 
mTOR to integrate the incoming signals and determine the appropriate response 
to these signals.
1,5
 
mTOR is highly conserved across eukaryotic species.
5
 In the cytosol, 
mTOR exists in two distinct complexes.
1,5,7
 mTOR complex 1 binds specific 
proteins that are different from the proteins mTOR complex 2 binds.
1,5
 mTOR 
complex 1 is responsible for determining cell’s metabolism, growth, and 
proliferation (cell division).
1,5
 It is sensitive to Rapamycin.
1,5
 Recently it was 
discovered that mTOR complex 2 is responsible for actin reorganization.
1,5,7
 Actin 
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is protein responsible for cell movement, shape and location. This complex is 
Rapamycin insensitive.
1,5,7
    
 Cells receive various signals such as growth factors (tell the cell when to 
grow), energy levels (AMP/ATP ratio), nutrient presence (presence of amino 
acids), and stress the cell experiences (for example, low oxygen levels).
1,5
 mTOR 
integrates these signals and determines the appropriate response. mTOR regulates 
ribosome biogenesis (whether or not to form ribosomes), transcription/translation 
(what genes to activate and what genes to deactivate), actin assembly (to move or 
not to move), macroautophagy (in time of starvation to begin degrading 
components of self).
1,5
  
 mTOR has been linked with many cancers such as melanoma, lymphoma, 
breast cancer and others.
2
 mTOR itself is not mutated in cancers usually.
2
 It is all 
the incorrect signaling the cancer cell experiences that allows mTOR to determine 
an inappropriate response.
2
 Cells with mTOR inappropriately activated can 
proceed with cell enlargement and cell proliferation in the absence of normal cell 
signaling.
2
 Rapamycin inhibits mTOR, making it unable to perform its function.
1,5
 
For this reason, Rapamycin has been used in cancer therapy.  For a cancer cell 
this means being unable to grow large and to divide.  
 In our laboratory we attempt to make cells larger either by synchronizing 
cell divisions to occur at the same time or by using therapeutic agents such as 
cytoskeleton-directed agents. Rapamycin is an agent that does the opposite, it 
makes cells smaller. We wanted to determine the effect of Rapamycin on human 
stem cells (normal cells) and human leukemia cells (cancer cells). Particularly, we 
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wanted to determine the concentration of Rapamycin that affects human stem 
cells (HSC) much more strongly than human leukemia cells (U937 cells). 
Ultimately we wanted to know if there is a concentration of Rapamycin that 
inhibits the cell size and cell proliferation of HSC but does not inhibit cell size 
and cell proliferation of U937 leukemia cells.  
 We performed experiments where we treated both HSC and U937 
leukemia cells with various Rapamycin concentrations and observed the effects of 
Rapamycin on cell enlargement and cell proliferation. In experiment 1 we treated 
both HSC and U937 cells with Rapamycin concentrations of 800, 400, 200, 100, 
50, and 25 nM. Both cell types showed cell size inhibition, meaning cells became 
smaller. At these concentrations there appeared to be no difference in the way 
Rapamycin affected HSC and U937 cells. HSC had cell size inhibited by 20% to 
30%. U937 cells had cell size inhibited by 12% to 30%. However, the effect was 
not uniform for both cell types. For example, HSC cells were inhibited the most 
by 50 nM Rapamycin concentration while U937 cells were inhibited the most by 
800 nM concentration.  
Both cell types showed cell proliferation inhibition as well. Both cell types 
should have been proliferating very little in the presence of Rapamycin. Indeed, 
HSC proliferated much less than the U937 cells did. However, U937 cells 
proliferated a lot more than we expected. For U937 cells proliferation was not 
dose dependent either, meaning, cells treated with 50 and 200 nM proliferated 
more than had cells treated with 100 and 800 nM Rapamycin.  
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In experiment 2 we treated only the U937 leukemia cells. In the previous 
experiment we saw that 800 to 25 nM Rapamycin had inhibitory effect on the 
U937 cells. In this experiment we treated U937 cells with lower Rapamycin 
concentrations 40, 20, 10, 5, 2 and 1nM because we wanted to determine the 
concentration of Rapamycin that would have no effect on cell size. We found that 
concentrations as low as 1 and 2 nM had an inhibitory effect on cell size of the 
U937 cells.  
Moreover, low concentrations of Rapamycin inhibited cell proliferation 
slightly. However, cells continued to proliferate despite the presence of 
Rapamycin. In experiment 2 we also removed Rapamycin a few days after 
treatment to see whether Rapamycin had any toxicity on cells growth. We found 
that there was no toxicity due to Rapamycin.  
In experiment 3 we treated both HSC and U937 cells with Rapamycin 
concentrations 32, 16, 8, 4, 2, 1, and 0.5 nM and compared the effect of 
Rapamycin on cell size and cell proliferation of both cell types. In terms of cell 
size, we did not find much difference in the way HSC and U937 responded to 
Rapamycin. We found that even low Rapamycin concentrations had an effect on 
cell size even of both HSC and U937 cells. However, in terms of cell proliferation 
there was a distinct difference in how the cells responded to Rapamycin. HSC 
cells proliferated very little or not at all in the presence of Rapamycin. When 
compared to non treated cells, at 2 nM Rapamycin HSC cells increased by 2-fold 
while U937 cells increased by 8-fold. This difference in cell number increase is 
startling.   
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 In summary, in terms of cell size we did not find a distinct difference 
between HSC and U937 cells. However, we found a startling difference in the 
way the cells responded to Rapamycin in terms of cell proliferation. Since 
Rapamycin and analogs of Rapamycin can control cell size by inhibiting cell 
growth, they are antagonistic to cytoskeletal-directed anticancer chemotherapeutic 
agents such as Vincristine, Taxol, and Cytochalasin B that can cause cancer cells 
to become greatly enlarged. In our laboratory we want to exploit inherent or 
chemotherapeutically-induced differences in cell size between normal cells and 
cancer cells in order to use outside physical force to preferentially destroy 
enlarged cells. In the future we would like to determine the effect of combination 
therapy of Rapamycin and cytoskeletal-directed agents. It is possible that HSC 
cells treated with Rapamycin and Vincristine, for example, will remain small 
while U937 cells will become preferentially big. These enlarged U937 cells would 
be subject to physical destruction while normal cells (HSC) are protected from the 
physical destruction by remaining small in size.   
 
 
